Background
NSCLC, tumor
OF LUNG ADENOCARCINOMA, TUMOR, NSCLC
C-mesenchymal-epithelial transition factor (c-MET) is a transmembrane receptor with autonomic phosphorylation activity encoded by Currently, several phase I and phase II studies have demonstrated the promising activity of MET tyrosine kinase inhibitors (TKIs), such as tepotinib, capmatinib and savolitinib, in NSCLC patients with c-MET dysregulation [BPI-9016M is a novel small-molecule TKI targeting both c-MET and AXL developed by Betta Pharmaceuticals Co., Ltd, Hangzhou, China., which can suppress tumor cell growth, migration and invasion of lung adenocarcinoma [